U.S. stocks declined for the third time in four days on Tuesday as health care companies took center stage.
Category: Gilead Sciences
3 Top Healthcare Stocks to Buy Now
… lthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
Why GlaxoSmithKline’s 2017 Guidance Is Conservative
Assuming that Advair will face competition from a substitutable generic in the US by mid-2017, GSK guided for flat to a slight decline in Core EPS at constant exchange rates. The stock is trading at a discount to five years average historical P/E vs. peers and some potential source of earnings upside is expected in 2017.
Cory Booker Blocks Importation Of Cheaper Drugs; Will Trump Clap Back?
… drugs: Trump has supported allowing consumers to re-import drugs from abroad, and mentioned having the Medicare health program for the elderly negotiate prices directly with pharmaceutical manufacturers. Both ideas have long been opposed by the …
Better Buy: Gilead Sciences, Inc. vs. Pfizer Inc.
However, when picking a stock, past performance isn’t nearly as important as what the future might hold. Which of these two drug stocks has an edge looking down the road? Here’s what the outlooks are for Gilead Sciences and Pfizer.
BRIEF-Gilead announces 144-week data evaluating safety and efficacy of Genvoya
* Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab
CytoDyn Strengthens Executive Management With Appointment of Anthony…
CytoDyn Inc. , a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus infection, announces the appointment of Anthony D. Caracciolo as Executive Chairman of CytoDyn effective immediately. In this new capacity, Mr. Caracciolo will assume an active leadership role in the Company’s strategic planning, business development and operations.
Newer Hepatitis C Drugs May Pose Health Risks
Jan. 25, 2017 — Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.
Health Highlights: Jan. 25, 2017
Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported.
Gilead Release: EMA Validates Company??’s Marketing Authorization…
… The review will follow an accelerated procedure reserved for medicinal products expected to be of major public health interest. Gilead also submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for SOF/VEL/VOX on December …
Should Investors Bet on Gilead Sciences Version 3.0?
Intercept Pharmaceuticals’ presentation at the J.P. Morgan Healthcare Conference could give a sneak peek at the future for Gilead Sciences. CEO Mark Pruzanski presented late Wednesday at the J.P. Morgan Healthcare Conference.
Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year
Despite a generally bleak year for Gilead, and for biotech stocks in general, shares of Exelixis, Inc. Can these biotechs continue climbing throughout the new year and beyond, or are they about to sputter and run out of fuel? Let’s look at what’s propelling them upward to see why they might be better picks than Gilead Sciences. A string of good news for Exelixis’ lead cancer drug made this one of the best-performing biotech stocks of 2016.
The Most Expensive Drugs of 2016
Prescription drug prices have gotten out of control for many Americans and many insurers, with some medications costing as much as premium sports cars, according to health-care investments analyst Keith Speights, writing for The Motley Fool. Speights recently reviewed the five most expensive drugs of 2016.
Gilead Sciences Has Bought Back $10 Billion of Stock in 2016. Should Investors Be Happy?
The stock has lost about 25% of its value in 2016, and management has taken advantage of the plunge by repurchasing about 100 million shares of its own stock. While it’s nice to know the shares were purchased at knockdown prices, it’s hard to remain cheerful when your stock price is sinking.
ContraVir expands mid-stage study of tenofovir prodrug analog into higher dose
ContraVir Pharmaceuticals broadens its ongoing Phase 2a study evaluating tenofovir exalidex against Gilead Sciences’ tenofovir disoproxil fumarate in patients with chronic hepatitis B virus infection by increasing the highest planned dose to 150 mg/day from 100 mg/day. The 84-subject sequential dose escalation study is assessing once-daily doses of TXL for four weeks against 300 mg of TDF once daily.
View Press Release
A Once-Daily Treatment that Demonstrated Comparable Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Tenofovir Disoproxil Fumarate — )–Gilead Sciences, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare has approved Vemlidy 25mg, a once-daily treatment for suppression of viral replication in chronic hepatitis B patients with evidence of hepatitis B virus replication and abnormal liver function. Vemlidy is a novel targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of tenofovir disoproxil fumarate 300mg.